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We studied the seminal vesicle secretion (SVS) of transgenic mice by using one-dimensional gel electrophoresis combined with
LTQ-FT ICR MS analysis to explore protein expression proﬁles. Using unique peptide numbers as a cut-oﬀ criterion, 79 proteins
were identiﬁed with high conﬁdence in the SVS proteome. Label-free quantitative analysis was performed by using the IDEAL Q
software program. Furthermore, western blot assays were performed to validate the expression of seminal vesicle proteins.
Sulfhydryl oxidase 1, glia-derived nexin, SVS1, SVS3, and SVS6 showed overexpression in SVS during cancer development. With
high sequence similarity to human semenogelin, SVS2 is the most abundance protein in SVS and is dramatically decreased during
the tumorigenic process. Our results indicate that these protein candidates could serve as potential targets for monitoring seminal
vesicle carcinoma. Moreover, this information can provide clues for investigating seminal vesicle secretion-containing seminal
plasma for related human diseases.
1.Introduction
Primary seminal vesicle carcinoma is an extremely rare
neoplasm; only a few cases have been reported [1, 2].
Seminal vesicle carcinoma is usually associated with diﬀuse
carcinomas of the bladder, prostate, or upper tracts. Very
few studies have been published on seminal vesicle invasion
[3], and the tumor biology of seminal vesicle carcinoma
is not well understood. The diagnoses of seminal vesicle
carcinoma are generally based on a combination of morpho-
logic, immunohistochemical, and radiological examinations.
However, it is diﬃcult to make a deﬁnitive diagnosis using
limited biopsy material.
The seminal vesicle makes up part of the male accessory
sexualglands.Afterpuberty,theglandsproduceaﬂuidcalled
seminal vesicle secretion (SVS), which accumulates in the
lumen of the seminal vesicles. SVS contains both protein
and nonprotein components and composes the majority of
seminal plasma. The extirpation of seminal vesicles from
adult rodents greatly reduces fertility, indicating that SVS
plays an important role in sperm activity and modiﬁcation
[4]. Some SVS proteins have been analyzed to characterize
their functions and physiological activities [5–9], but the
constituents of the SVS proteome have not been well studied.
Proteomic studies are broadly applied to the diagnostic,
prognostic, and therapeutic ﬁelds. In terms of disease
diagnosis and prognosis, body ﬂuid analysis proves to be
more attractive than tissue analysis because it provides
several advantages including low invasiveness, minimum
cost, and easy sample collection and processing [10]. The2 International Journal of Proteomics
linear ion trap-Fourier transform ion cyclotron resonance
mass spectrometer (LTQ-FT ICR MS) has been exploited
as a tool for identifying and characterizing isolated proteins
[11]. Combining LTQ-FT ICR MS with liquid chromatog-
raphy, large-scale and high-quality proteomic analyses of
several body ﬂuids are achievable, including tears, urine,
and seminal plasma [12–14]. By virtue of its capacity for
exhaustive investigation, proteomic research has aroused
high expectations for the discovery of biomarkers of various
diseases [15, 16].
In this work, we used the transgenic mouse TAg as an
animalmodeltostudyseminalvesiclecarcinoma.Transgenic
mouse TAg (C57BL/6-TgN (TRAMP) 8247Ng) expresses an
SV40 large T antigen that is driven by the probasin promoter
[17]. In addition to being models for prostate cancer, TAg
mice also develop other tumors, including neuroendocrine
tumors in the prostate and neoplasms in the seminal vesicles.
We analyzed the SVS proteome by using one-dimensional
PAGE and LC LTQ-FT ICR MS. Accurate masses of tryptic
peptides were measured by FT ICR MS, and tandem mass
(MS/MS) experiments were performed in LTQ to acquire
adequate data for proteomic identiﬁcation. The resulting
mzXML format data and Mascot search results were applied
to perform label-free quantitative analysis. Moreover, we
used western blot assays to validate the quantitative results.
2.MaterialsandMethods
2.1. Animals and Histopathology. T A gm i c ew e r ep u r c h a s e d
from the Jackson Laboratory (Maine, USA), and wild type
C57BL/6JNarl normal control mice were obtained from
the National Laboratory Animal Center (Taipei, Taiwan).
They were housed in a speciﬁcally pathogen-free facility
and handled in accordance with the guidelines of Guide for
the Care and Use of Laboratory Animals. All of the mice
were given free access to a standard murine chow diet and
reverse osmosis water and were maintained on a 14:10
hours light-dark cycle at 21–23
◦C. In this study, TAg mice
(n = 21; n = 7 for each subgroup) of various ages (32–40
weeks) and normal control mice (n=6) were euthanized and
the seminal vesicles and prostate glands were processed for
histopathologic examination.
2.2. Sample Collection and Preparation. The seminal vesicles
were collected by careful dissection to free them from the
adjacent coagulating glands, and SVS was squeezed directly
into 5mL of 8M urea solution. Small amounts of coagulated
pellets were removed through centrifugation at 15,000g for
10 minutes. The protein concentration of the supernatant
was determined using the Bio-Rad Protein Assay (Bio-Rad
Laboratories, Calif, USA) by the measurement of A595. Each
20μg of SVS proteins was applied to 13% PAGE, and the
gel was subsequently visualized through coomassie blue-
staining. Gel lanes were divided into 10 sections and all
slices were cut into small gel pieces (<1mm 3), followed by
in-gel digestion. Additionally, ﬁve of the observed major
bands were cut for independent assays. Brieﬂy, the procedure
of in-gel digestion included the following steps in order:
(a) destaining with 50% acetonitrile (ACN) and 25mM
ammonium bicarbonate (ABC); (b) reduction using freshly
prepared 10mM dithiothreitol for 45 minutes at 58
◦C;
(c) alkylation using freshly prepared 55mM iodoacetamide
for 45 min at room temperature in the dark; (d) enzyme
digestion with 4ng/μL sequencing grade trypsin in 25mM
ABC solution at 37
◦C for 16–18 hours; (e) extraction of
tryptic peptides using a 60% ACN/1% triﬂuoroacetic acid
solution. After drying to remove the solvent, the re-dissolved
tryptic peptides were subjected to LC LTQ-FT ICR MS
analysis.
2.3. LC LTQ-FT ICR MS Analysis. MS/MS experiments were
performed with an LTQ-FT ICR MS (Thermo Electron,
Calif, USA) equipped with a nanoelectrospray ion source
(New Objective, Mass, USA), an Agilent 1100 Series binary
HPLC pump (Agilent Technologies, Calif, USA) and a
Famos autosampler (LC Packings, Calif, USA). Tryptic
peptide mixtures were injected at a 10μL/min ﬂow rate
into a self packed precolumn in line with a reverse phase
C 1 8n a n o c o l u m n( 7 5μmI . D .× 200mm) that used Magic
C18AQ resin (particle size, 5μm; pore size, 200 ˚ A; Michrom
Bioresources, Calif, USA). The analytic program was set
at a linear gradient from 10% to 50% ACN with a 60
minutes running cycle and a split ﬂow rate of 300nL/min.
The full-scan survey MS experiment (m/z 320–2,000) was
executed in FT ICR MS with a mass resolution of 100,000
at m/z 400. The top ten most abundant multiply charged
ions, if they were above a minimum threshold of 1,000
counts, were sequentially isolated for MS/MS by LTQ.
Singly charged ions were rejected for MS/MS sequenc-
ing.
2.4. Mascot Search. The raw ﬁles of spectra were converted
to mgf ﬁles with Mascot Daemon (data import ﬁlter: mass
range, 600–5400; grouping tolerance, 1.4) and merged into
a single ﬁle for searching by the MASCOT (version 2.1,
Matrix Science Ltd., London, UK) software platform based
on the IPI mouse database (v 3.36). The following MASCOT
parameter settings were used; the peptide tolerance was
15ppm with 2+ and 3+ peptide charges and the MS/MS
tolerance was 0.6Da. Two missed cleavages by trypsin
were allowed, carbamidomethyl (C) was used as a ﬁxed
modiﬁcation and oxidation (M) and deamidated (NQ) were
usedasvariablemodiﬁcations.Thesigniﬁcancethresholdfor
the identiﬁcation was set to P<. 01.
2.5. Label-Free Quantitative Analysis. A software program
IDEAL-Q (ID-based Elution time Alignment by Linear
regression Quantiﬁcation) was developed in-house to
analyze LC-MS/MS data for label-free quantitative analysis
[18]. The program was used to process the LC-MS data
and the search results obtained from the Mascot search
engine to extract the quantiﬁcation information. The whole
quantitativeanalysisconsistedofthefollowingtasks.(I)Data
preparationandconstructionoftheproteinlist.Therawdata
ﬁles generated from the mass instrument were converted
into the mzXML data format by the ReAdW programInternational Journal of Proteomics 3
(http://tools.proteomecenter.org/wiki/index.php?title=Soft-
ware:ReAdW). The data of each fractional LC-MS/MS
runs coming from the same sample were merged and then
searched by the Mascot search engine to establish a protein
list, which contained identiﬁed proteins and their related
peptide information. The mzXML ﬁles coupled with the
peptide and protein identiﬁcation results were input to the
IDEAL-Q program. (II) Extracting quantitative information
from each LC-MS run. For quantitative analysis of a peptide
in an LC-MS run, we extracted the LC-MS data within the
range of ±1.5 minutes of its elution time and ±3.5Da of the
precursor m/z value. The peak clusters located within the
selected elution time and the precursor m/z value from the
extracted data underwent a peptide validation process. For
peptide validation, the following three criteria were applied:
signal-to-noise ratio (S/N), charge state (CS), and isotope
pattern (IP). The S/N criterion checks whether the precursor
peak has a valid S/N ratio (>2). The CS criterion eliminated
the peak clusters with an incorrect charge state by examining
whether the distance between adjacent peaks is equal to 1/z
(tolerance ±1/10 1/z). Finally, the IP criterion examined the
correlation between isotopic distribution of the observed
peak intensities and the theoretical isotopic distribution
of the peptide. The correlation was then evaluated by a
Chi-square goodness of ﬁt test (<0.218). The purpose of
peptide validation was to ﬁlter out false peptide signals; only
the peptide passing the validation criteria were processed
to subsequent quantiﬁcation. We used the extracted ion
chromatogram (XIC) to determine peptide abundance in
an LC-MS run. (III) Peptide abundance and peptide ratio
processing. First we determined the abundances of valid
peptides in each LC-MS run. Then we calculated the peptide
abundanceinafractionbyaveragingthepeptideabundances
of all repeated runs. We summed the peptide abundances in
all fractions to represent the peptide quantity in the sample.
Following, the peptide ratio between samples could be
calculated. (IV) Protein abundance processing. We selected
nondegenerate unique peptides and performed Dixon’s
test to eliminate outliers of peptide ratios for each protein.
We then used the top three highly abundant peptides of
one protein to represent the quantity of this protein by a
weighted average.
2.6. Western Blot. Polyclonal antibodies against SVS1, SVS2,
SVS3 [19], SVS5, SVS7 [20], sulfhydryl oxidase 1, glia-
derived nexin, carcinoembryonic antigen-related cell adhe-
sion molecule 10 (CEACAM 10) [7], Lysozyme C-type M,
secreted seminal-vesicle Ly-6 protein 1 (SSLP-1) [21], serine
protease inhibitor kazal-like protein (SPINKL) [22], and ser-
ine protease inhibitor Kazal-type 3 (SPINK3) [9] were raised
in New Zealand White rabbits. Antibody against human
albumin, which also crossreacted with mouse albumin, was
purchased from Calbiochem (Darmstadt, Germany). After
PAGE separation, proteins were transferred to a PVDF
membrane using a semidry blotter (ATTA, Tokyo, Japan).
The electrophoresis program was set with a constant current
(1.5mA/cm2) for 1 hour. The membrane was blocked with
5% (w/v) skim milk in phosphate-buﬀered saline (PBS) at
room temperature for O/N reaction, and then incubated
with primary antibody (1:5000) in PBS with 2% (w/v) skim
milk for 1 hour. After gentle agitation in four changes of
PBST (PBS with 0.05% Tween 20) for 15 minutes each, the
membrane was immuno-reacted with secondary antiserum
(horseradish peroxidase-conjugated goat antirabbit IgG,
Amersham Pharmacia) diluted to 1:10000 in PBS with 2%
(w/v) skim milk for 1 hour. Immuno-reactive bands were
revealed using an enhanced ECL substrate according to the
manufacturer’s instructions (Pierce, Illinois, USA).
3. Results
3.1. Histopathology and Tumor Categories. According to the
histopathologic results, the neoplasm development of the
accessory sex gland was categorized into three stages: (I)
hyperplasia of the seminal vesicle (Hp), (II) adenoma of
the seminal vesicle (Ad), and (III) adenocarcinoma of the
seminal vesicle with prostate cancer (Ac) (Figure 1). The
Hp stage showed a typical hyperplasia area. These areas,
which were characterized by small size and uniformity
of cells and nuclei, appeared to have increased glandular
enfolding and lack of mitoses. The Ad stage showed the
replacement of most of the normal glandular parenchyma
with tumor masses encompassing two main components,
epithelial cells and stromal cells. The cuboidal to columnar
epithelialcellswerearrangedinmultiplepapillaryfrondsand
glandular structures, which were separated and supported
by abundant, immature, and ﬁbrovascular stroma. However,
mitotic ﬁgures were infrequent. At the Ac stage, the seminal
vesicular tumor showed an appearance similar to the Ad
stage, except that sometimes hemorrhage occurred in the
seminal vesicles. Prostatic adenocarcinoma of the Ac stage
appeared as intraluminar cribriform to papillary epithelial
proliferations that completely or almost completely ﬁlled the
lumen of several adjacent alveoli. The epithelium that lined
the tumors was composed of bland-appearing, cuboidal to
tall columnar epithelial cells with maintenance of nuclear
polarity and sometimes with basophilic cytoplasm.
3.2. Protein Pattern and Proteomic Analysis. Three SVS sam-
ples of each group were pooled for the proteomic measure-
ments. SVS proteins were separated by PAGE and their pro-
ﬁle was presented by coomassie blue staining (Figure 2). The
protein proﬁle was dominated by a small number of highly
expressed proteins. The protein distribution of normal SVS
was diﬀerent from those coming from the tumorous SVS,
which displayed more complex protein contents. Based on
protein pattern comparison, ﬁve major bands were chosen
as reference indicators. Bands A and E showed upregulated
expression, while band B showed downregulated expression
in the tumorous SVS. MS/MS was used to analyze the major
proteins in bands A to E, which were identiﬁed as albumin,
seminal vesicle secretory protein 2 (SVS2), SVS4, SVS5, and
hemoglobin beta, respectively. The serum proteins, albumin,
and hemoglobin beta, are obviously increased in SVS in the
early stages of tumorigenesis.4 International Journal of Proteomics
(a) (b)
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Figure 1: Histopathologic section and tumor categories. Tissue slices from seminal vesicles of normal and various tumor stage mice were
stained with hematoxylin-eosin. (a) Normal seminal vesicle, (b) Hp stage seminal vesicle, (c) Ad stage seminal vesicle, and (d) Ac stage
prostate with carcinoma. Photographs display the images with original magniﬁcation ×10. Scale bar, 75μm.
The proteomic analyses of four groups of SVS, which
were normal, Hp, Ad, and Ac, were performed by repeated
experimental runs. As a consequence of these analyses,
excluding single peptide or single unique peptide matched
proteins and keratins that were frequent contaminants in
proteomic analysis, 179 proteins met the search criterion
and were identiﬁed in the proteome by combining four
kinds of samples. In order to further improve conﬁdence in
the identiﬁed proteins, the reproducibility of the matched
unique peptides found in every SVS sample was considered
asanindextosiftthroughtheproteinlist.Thedetermination
of unique characteristics for a peptide was based on the
proteotypic peptide sequence that could only match to one
protein through the IPI mouse database. The number of
uniquepeptidesforoneproteinwassummedwiththeresults
of proteomic analyses of the four groups of SVS; therefore,
not all peptide signals could be found in the four groups of
SVS.Generally,asmallernumberofuniquepeptidescoupled
with a lower detection rate. We deﬁned the undetectable rate
as the average percentage that could not ﬁnd the matched
unique peptides at the designated unique peptide number in
the four groups of SVS. With the unique peptide numbers 2,
3, 4, and 5, the undetectable rate was 27.7%, 28.0%, 27.6%,
and 12.5%, respectively. When the unique peptide number
was more than 5, the undetectable rate decreased to zero
(Figure 3). Thus, we chose the unique peptide number 5
as a cut-oﬀ criterion to ﬁnalize the SVS proteome. Based
on this condition, 79 proteins were included in the SVS
proteome (Table 1). Among this proteome, 47 proteins were
secreted or serum proteins that were the most abundant in
this proteome and 16 proteins belonged to seminal vesicle
proteins that have been identiﬁed or characterized at the
previous studies. In addition, a small number of intracellular
proteins, including cytoplasm protein, lysosome protein,
endoplasmic reticulum protein, and membrane protein were
also found in this proteome.
3.3. Label-Free Quantitative Analysis. To assess the relative
proteinexpressionlevelsatnormalandvariouscancerstages,
quantitativeproteomicanalysiswaspursuedbyusingalabel-
free quantitative approach, which adopted the average peak-
area of the three most intense peptides for the identiﬁed
proteins to represent the absolute protein abundance [23].
The in-house developed program IDEAL-Q [18]w a su s e d
to analyze LC-MS data and the corresponding MASCOTInternational Journal of Proteomics 5
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Figure 2: Protein pattern of SVS. SVS proteins were separated by 13% PAGE and visualized by coomassie blue staining. N, normal; Hp, Ad
and Ac, various tumor stages. Molecular weights of protein markers are shown on the left. Designated bands A–E were identiﬁed by MS/MS,
and the names of the major proteins are shown on the right.
23456 > 6
0
5
10
15
20
25
30
Number of unique peptide
U
n
d
e
t
e
c
t
a
b
l
e
r
a
t
e
(
%
)
Figure 3: The relationship of unique peptide number and the
undetectable rate. The undetectable rate was deﬁned as the
percentage of proteins without identiﬁable peak-areas in the same
unique peptide number group.
search results to extract the quantiﬁcation information.
The results obtained from this quantitative calculation are
illustrated in Table 1. The stoichiometric distribution of
protein abundance was from 3.26 × 104 (Dickkopf-like
protein 1) to 2.77 × 109 (SVS2), which meant that the
dynamic range for protein detection reached ﬁve orders of
magnitude by using the described method. To estimate the
applied quantity of SVS proteins for proteomic analysis, the
total protein abundances were summed and were 3.31 ×
109,9.74 × 108,1 .05 × 109,a n d9 .85 × 108 for normal, Hp,
Ad,andAc,respectively.Theresultsshowedthatthequantity
of SVS proteins between various cancer stages was within a
10% diﬀerence, but the quantity of normal SVS was three
times more than other samples, which appeared to conﬂict
with the gel patterns (Figure 2). We further compared the
diﬀerence of expression levels of SVS2 and SVS4 (or SVS5)
of normal SVS, which displayed almost equal intensity on
PAGE gel by dye staining. SVS2 showed a protein abundance
of 2.77 × 109, which was about 200-fold higher than SVS4
at 1.29 × 107 (or 150-fold higher than SVS5 at 1.76 × 107).
This result implied that quantiﬁcation errors could occur
with the comparison of various molecular weight proteins.
To acquire the protein content distribution for realizing
the eﬀect of using this quantitative analysis method, the
abundance of every protein was converted to the percentage
of content in every SVS sample. The results illustrated that
SVS2,SVS4,andSVS5were83.7%,0.4%and0.5%innormal
SVS proteins, respectively (Table 1). In the SVS of the Hp
stage, the low molecular weight proteins SVS4, SVS5, and
hemoglobin beta were 1.4%, 1.2%, and 2.0%, respectively,
which were signiﬁcantly less than SVS2 at 33.0%. Compared
with the gel pattern, the levels of low molecular weight
proteinstendedtobeunderestimated,whichleadtoerrorsin
measuring protein quantity or determining the percentageof
protein content.
The relative expression levels of tumorous versus nor-
mal conditions were achieved by calculating the ratios of
absolute SVS protein abundances (Table 1). Among sem-
inal vesicle proteins, SVS1, SVS3, and glia-derived nexin
showed upregulated expression with ratios greater than 2.
With respect to downregulated expression, lysozyme C and6 International Journal of Proteomics
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seminal vesicle antigen were decreased two times lower than
their normal value. SVS2, with a 10-fold decrease, was
the most diﬀerentially expressed protein. Similar diﬀerences
were also observed in the gel patterns. In addition, most
serum proteins (35/46, 76%) had an upregulated expression
in the tumorous SVS. This phenomenon could relate to the
physiological change of seminal vesicles that increases the
vascular permeability for serum proteins to enter the lumen
of the seminal vesicle.
To evaluate the reproducibility of MS analysis, coeﬃcient
ofvariation(CV)values(%)ofthetopthreehighlyabundant
peptidesinrepeatedrunswerecalculatedandtheaverageCV
values are listed in Table 1. In this work, the total average
CV values for normal, Hp, Ad, and Ac samples were 16.4%,
15.1%, 10.8%, and 11.5%, respectively.
3.4. Western Blot Validation. The eﬀects of tumorigenesis on
theexpressionofseminalvesiclesecretoryproteinswerecon-
ﬁrmed by western blot analyses, which were also performed
to validate the quantiﬁcation results of the MS analyses
(Table 1). Because no protein has been demonstrated to
have constitutive or consistent expression in SVS, we used
the same loading quantity as the quantitative control in
this study. Based on MS quantiﬁcation, more than 75%
of serum proteins showed upregulated expression in the
tumorous SVS. Using western blot analysis, for example, the
higher levels of albumin were clearly demonstrated in the
tumorous SVS, which was consistent with the MS results
(Figure 4). Many SVS proteins were also analyzed by the
produced antibodies to verify their expression. The signal
intensities of western blot were quantitatively measured by
the software ImageJ (http://rsb.info.nih.gov/ij/) [24], and the
relative expression ratios compared with the normal samples
were calculated (Figure 4(c)). Sulfhydryl oxidase 1, glia-
derived nexin, SVS1 and SVS3 showed upregulated expres-
sion, but SVS2, CEACAM 10, lysozyme C-type M, SVS5,
SSLP-1, SVS7, SPINKL, and SPINK3 showed downregulated
expression. Regardless of upregulation or downregulation,
most SVS proteins changed their secretion depending on
the carcinogenesis progress. The protein expression levels
revealed a few discrepancies in comparison with the western
blot and MS quantiﬁcation methods. For example, SSLP-1
showedlittlechangeduringtumorigenicprocessbyusingMS
analysis;however,ithadacleardecreasingpatternbywestern
blot. On the whole, the western blot results were in good
agreement with the MS quantiﬁcation.
4. Discussion
4.1. Tumorigenesis Aﬀects the Composition of the SVS Pro-
teome. SVS, one of the major contributors to seminal ﬂuid,
is important for semen coagulation and plays an important
role in promoting sperm motility and suppressing immune
activity in the female reproductive tract. Only 16 speciﬁc
seminal vesicle secretory proteins have been identiﬁed with
high conﬁdence in the SVS proteome, which is a relatively
simple system compared to other body ﬂuids. Almost all SVS
proteins make changes in their levels during the tumorigenic
process. Compared with increasing protein expression, the
suppression eﬀect produced by tumorigenesis on protein
expression is more remarkable. The expression of SVS2,
SVS5, and lysozyme C-type M decreased 5- to 10-fold at
the Ac stage by MS analysis or western blot assay. Although
the functions of most SVS proteins in the reproductive
system are not fully understood, previous studies have
demonstrated that SVS proteins involved in formation of the
copulatory plug have the abilities to enhance sperm motility
and act as decapacitation factors to modulate the fertilizing
ability of spermatozoa. They also have activity of serine
protease inhibitors and antimicrobial activity, which may
be involved in fertility (Table 2). According to the current
study, the physiological functions of SVS proteins did not
show a deﬁnite correlation with the eﬀects of tumorigenesis.
For example, SVS1, SVS2, and SVS3 are the components
of copulatory plug formation; however, SVS1 and SVS3
showed upregulated expression, but SVS2 showed downreg-
ulated expression. As serine protease inhibitors, glia-derived
nexin and SVS6 showed upregulated expression, but SVS5,
SPINKL, and SPINK3 showed downregulated expression.
Thus, the changes of seminal vesicle proteins during the
tumorigenic process need to be explored individually. Based
on our studies, almost all seminal vesicle secretory proteins
were aberrantly expressed by tumor cells. Only a few seminal
vesicle proteins have been demonstrated to correlate with
the occurrence of carcinoma (Table 2). The expression of
sulfhydryl oxidase 1, glia-derived nexin, and SVS6 increased
in seminal vesicle carcinoma and other carcinomas. The
results suggest that the expression of these proteins could be
under similar regulation in various carcinoma systems.
SVS2, the most abundant protein in SVS, decreased
duringseminalvesiclecarcinoma.SVS2shows55%sequence
similarity to human semenogelin, which is the major struc-
tural component of gelatinous coagulum. Semenogelin is
able to protect sperm from protein tyrosine phosphorylation
and to prevent induction of the acrosome reaction [38].
A member of the gene family that encodes this semen-
coagulating protein is commonly found in mammalian
species [6, 39–41]. As a decapacitation factor, SVS2 can bind
sperm to aﬀect fertility in the female reproductive tract.
Decreased levels of SVS2 at the tumorigenic stages could
diminish its inhibition of sperm mobility in a concentration-
dependent manner [33]. In addition to varying biological
activities, the change of the SVS2 protein level could provide
a useful target to monitor the progress of seminal vesicle
carcinoma.
4.2. Vascular Permeability Contributes to the Elevated Levels of
Serum Proteins in SVS. Many serum proteins showed upreg-
ulation in the tumorous SVS (Table 1). The most strikingly
expressed proteins, albumin and hemoglobin β,c o u l db e
observed on the coomassie blue-stained gel (Figure 2). The
expression of albumin was also conﬁrmed by western blot
assay (Figure 4). Basal levels of serum proteins could be
considered to come from contamination by surgical leaks.
However, elevated levels of serum proteins may originate
from other sources. First, the mutant secretory cells ofInternational Journal of Proteomics 11
Upregulated expression
Downregulated expression Relative expression ratio
NH pA d A c
NH pA d A c
NH pA d A c
NH pA d A c
NH pA d A c
NH pA d A c
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NH pA d A c
NH pA d A c
NH pA d A c
NH pA d A c
NH pA d A c
NH pA d A c
(1) Albumin
(2) Sulfhydryl oxidase
(3) Glia-derived nexin
(4) SVS 1
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(1) SVS 2
(2) CEACAM 10
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Figure 4: Western blot analysis. The expression of albumin, sulfhydryl oxidase 1, glia-derived nexin, SVS1, SVS3, SVS2, CEACAM 10,
Lysozyme C-type M, SVS5, SSLP-1, SVS7, SPINKL, and SPINK3 were examined using polyclonal antibodies. (a) proteins with upregulated
expression; (b) proteins with downregulated expression; (c) relative expression ratios compared to normal SVS.
the seminal vesicles may produce and secrete them into
the lumen, meaning that they are endogenous proteins.
Second, angiogenesis or vascular permeability results in the
movement of proteins from the blood into the seminal
vesicle lumen. To evaluate this phenomenon, we used
microarray gene chips to examine the mRNA expression in
the seminal vesicles from the four stages. The results showed
that the expression of albumin, hemoglobin, apolipoprotein,
and α1-antitrypsin remained at background levels (data
not shown). This suggested that these serum proteins are
excluded from being newly synthesized under tumorigenic
conditions in seminal vesicles, and that angiogenesis or
vascular permeability is responsible for the increase in their
levels.Vascularpermeabilityisatightlyregulatedprocessthat
is often an essential response accompanying angiogenesis,
tumor metastasis, or inﬂammation [42]. Thus, there is a
reasonable explanation for late (Ac) stage SVS to have a pink
or red appearance.
4.3. Label-Free Quantitative Analysis. Combining one-
dimensional PAGE fractionation techniques with LC MS/MS
analysis is a popular approach for proteomic research
[43, 44]. Due to simplicity and ﬂexibility, the label-free
quantitative strategy is an attractive alternative for the
quantiﬁcationof LC MS/MS-basedproteomics. Inthis study,
our experimental data were analyzed by using the self-
developed program IDEAL-Q, which was designed to reduce12 International Journal of Proteomics
Table 2: Summary of seminal vesicle secretory proteins identiﬁed in mouse SVS.
Expression
Protein Function Reference Mass Western Cancer-related studies
Upregulated expression
Sulfhydryl oxidase 1 Catalyze disulﬁde bond
formation
[25] ⇑⇑ [26, 27]
Glia-derived nexin Serine protease inhibitor [8] ⇑⇑ [28, 29]
Seminal vesicle secretory protein 1
Amine oxidase
activity/Copulatory plug
formation
[5] ⇑⇑ —
Seminal vesicle secretory protein 3a Copulatory plug
formation
[19] ⇑⇑ —
Seminal vesicle secretory protein 3β Copulatory plug
formation
[30] ⇑⇑ —
Seminal vesicle secretory protein 6 Serine proteinase
inhibitor
[31] ⇑ —[ 32]
Downregulated expression
Seminal vesicle secretory protein 2
Semen-coagulating
protein/Sperm
decapacitation factor
[6, 33] ⇓⇓ [34]
Carcinoembryonic antigen-related cell
adhesion molecule 10
Sperm binding and
enhancement of sperm
motility
[7] ⇓⇓ —
Lysozyme C, type M Primary bacteriolysis — ⇓⇓ —
Seminal vesicle secretory protein 5 Serine proteinase
inhibitor
[35] ⇓⇓ —
Secreted seminal-vesicle Ly-6 protein 1 Potential cellular
adhesion and signaling
[21] ⇔⇓ —
Seminal vesicle secretory protein 7 Sperm capacitation
factor
[20] ⇓⇓ —
Serine protease inhibitor kazal-like
protein
Serine protease
inhibitor/Sperm
decapacitation factor
[22] ⇓⇓ —
Serine protease inhibitor Kazal-type 3
Serine protease
inhibitor/Sperm
decapacitation factor
[9] ⇓⇓ —
Seminal vesicle antigen Sperm decapacitation
factor
[36] ⇓ ——
Seminal vesicle secretory protein 4
Anti-inﬂammatory and
immune-modulating
agent
[37] ⇔ ——
the errors in peak detection and drift of retention time, and
to validate the selected peptides by the criteria of signal-to-
noise ratio, charge state, and isotope pattern. The average
CV values were in the range of 10–17% for the top three
most abundant peptides, which demonstrated that accurate
peak detection and reproducibility could be acquired by
using the analytical program IDEAL-Q. However, errors
will occur in the analysis of low molecular weight proteins
by using the top three most abundant peptides for quan-
titative analysis, as found in a previous study [38]. The
enzymatic reaction produces various peptides with a wide
range of ionization eﬃciency during MS analysis. Smaller
proteins will have fewer enzymatic peptides to choose from
the highest ionization eﬃciency region to represent their
quantity. Therefore, underestimation is inevitable for the
quantiﬁcation of low molecular weight proteins. For the
relative quantiﬁcation of speciﬁc protein abundance changes
under various conditions, such kinds of quantiﬁcation error
may not aﬀect the comparison of protein ratios. However,
to achieve the accurate absolute quantiﬁcation, modifying
the original results with parameters regarding molecular size
needs to be further pursued.
5. Conclusion
To obtain SVS samples from humans is quite diﬃcult;
therefore, SVS samples from a mouse model system wereInternational Journal of Proteomics 13
chosen as an alternative research target, although the volume
and composition of SVS diﬀers signiﬁcantly between various
species of mammals. Based on proteomic analysis, we
identiﬁed 79 proteins, including 16 seminal vesicle secretory
proteins, in the SVS proteome. Label-free quantitative anal-
ysis was performed to estimate the quantity of the identiﬁed
proteins. Moreover, most seminal vesicle secretory proteins
were subjected western blot assay to further validate their
expression. Our data showed that both approaches were in
good agreement with each other. We conﬁrmed that many
SVS proteins had diﬀerential expression proﬁles during the
tumorigenicprocess,especiallySVS2,withasequencesimilar
to human semenogelin, which was dramatically decreased
during the primary stage of seminal vesicle carcinoma. The
information obtained from the transgenic mice could be
helpfulinunderstandingtumorbiologyandcouldbefurther
applied as a reference to study related human diseases.
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